CA2023367A1 - Substances with heparin-like structure and their method of production - Google Patents
Substances with heparin-like structure and their method of productionInfo
- Publication number
- CA2023367A1 CA2023367A1 CA 2023367 CA2023367A CA2023367A1 CA 2023367 A1 CA2023367 A1 CA 2023367A1 CA 2023367 CA2023367 CA 2023367 CA 2023367 A CA2023367 A CA 2023367A CA 2023367 A1 CA2023367 A1 CA 2023367A1
- Authority
- CA
- Canada
- Prior art keywords
- heparin
- acetic anhydride
- activity
- uronic
- desulfated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Landscapes
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SUBSTANCES WITH HEPARIN-LIKE STRUCTURE AND THEIR METHOD OF
PRODUCTION
ABSTRACT OF THE DISCLOSURE
Process for the synthesis of a new N-acetylated Heparin derivative, by reaction of a N-desulfated Heparin with acetic anhydride, new compound so obtained and pharmaceutical compositions containing it, endowed with antithrombotic and fibrinolitic properties with low anticlotting ativity.
PRODUCTION
ABSTRACT OF THE DISCLOSURE
Process for the synthesis of a new N-acetylated Heparin derivative, by reaction of a N-desulfated Heparin with acetic anhydride, new compound so obtained and pharmaceutical compositions containing it, endowed with antithrombotic and fibrinolitic properties with low anticlotting ativity.
Description
L ~ ; 3 SUBSTANCES WITH HEPARIN-LIKE STRUCTURE AND TH~IR METHOD OF
PROI)UCTION
Natural glucosaminoglycans obtained by extraction, (GAG), such as the Heparansulfate (HS), have been isolated and characterized (Jorpes, J. - Gardell, S.JBC 176, 267-276). Their structure is similar to the Heparin one, varying fundamentally in the degree of N-acetilation: in the Heparin, the group -NH of the glucosamine is preferably sulfated, instead, in the HS, is N-acetilated.
As a consequence of said structural difference, the HS shows peculiar biological characteristics, different from those of the Heparin:
1) It has low anticlottig activity tested in vitro (APTT, anti-X).
PROI)UCTION
Natural glucosaminoglycans obtained by extraction, (GAG), such as the Heparansulfate (HS), have been isolated and characterized (Jorpes, J. - Gardell, S.JBC 176, 267-276). Their structure is similar to the Heparin one, varying fundamentally in the degree of N-acetilation: in the Heparin, the group -NH of the glucosamine is preferably sulfated, instead, in the HS, is N-acetilated.
As a consequence of said structural difference, the HS shows peculiar biological characteristics, different from those of the Heparin:
1) It has low anticlottig activity tested in vitro (APTT, anti-X).
2) It shows proPibrinolitic activity (release of the plasminogen tissular activator), when used in humans or in laboratory animals.
3) It presents a superior bioavailability to that of Heparin.
ZO Therefore, said substances are specially relevant to cardiovascular medicine, mainly, in long-lasting therapies intended to prevent the formation of microthrombus, as well as to contribute to their dissolution. This can be achieved with little risk of hemorrhages and with reduced side ePfects.
Obviously, these natural mucopolysaccharides cannot be , ~
' ;
6~ ? r` ~
extracted in large scale, due to their low concentration in the tissular mass. This can limit significatively its extensive use in the therapeutical field.
Now, in accordance with the patent application, a process has been developed, which permits to obtain a pure N-acetilated compound with a Heparin-like structure with good yields, starting from Heparin as raw material.
The process of the invention is based upon a controlled hidrolysis of the Heparin with N-desulfatation without depolimerization, followed by the introduction of the acetyl group in the specific position of the aminic N, through a reaction using acetic anhydride.
The Heparin desulfatation is achieved specifically on the amino group, without hydrolizing the group O-sulfate and without producing hidrolysis of the glycosidic bond or other parasitic reactions. This has already been described by Inoue and Nagasawa (1975~ "Inoue, Y. - Nagasawa, K. Carbohyd, Res. 46, 87-95 (1976)". However, this method cannot be easily conducted at large scale, since it works on a heparin-piridynic complex dissolved in zO acqueous or methanolic dimetilsulfoxide with its associated problems, for example: the separation of the complex from the reacting solvent, the quantitative ellmination of the pyridine, the recovery o~ expensive solvents, etc.
On the contrary starting from calcium Heparin, due to the contra-ion size, a selective N-desulfatation in an acid acqueous .: ,: . :: . :
~ : : . : . ::.
medium can be achieved, without causing structural alterations and without affecting the medium MW.
Particularly, the browning of the product and the hydrolysis of the O-sulfate group are avoided.
Then, the partially N-desulfated Heparin (Intermediate A), is subjected to the acetylation reaction.
The Heparin acetylation has been described by Danishefsky (Danishefsky, N. Meth. Carb. Chem. ~, (85), 11) and Nagasawa as well (Inoue, Y. - Nagasawa, K. Carbohyd, Res. 46, 87-95 (1976)).
Both of them work with great quantities of acetic anhydride, pH-6,5-7,o and a wide range of temperatures.
In these conditions, and working at low temperatures lO-5 C), a parasitic O-acetylation is produced over the free -OH of the disaccharidic unit.
It has been discovered, and it is the object of the present invention, that when using a quantity practically stoichiometric of the acetic anhydride (1-1,1 moles (CH,CO) =O/Mol of the free-amino N, previously determined by the titration curve and at a pH
between to 9,3 and 9,5 (maximun limit compatible whit the acetic anhydride hydrolisis), the N-acetylation is exclusively produced, even working at 25-30C.
At this temperature, the reaction is fast and complete within 15 minutes. Even if the reaction is lasted for a longer time, it does not produce secondary reactions.
The obtained product (final product B) has an extremely .
constant composition and is represented by a molecule chemically well characterised, with a precise analitical description, as defined in the following table and figures.
To better identify the product object of the present invention the 3C-NMR characterisation of the product is hereby described.
The NMR spectrum of the final product 8 (figure 1), was determined in D20 solution, at 75 MHz, by means of a Brucker Mod.
CxP-300 spectrometer. For comparison purposes also the spectra of a standard Heparin (figure 2) ad of Heparansulfate tHS, figure 3) are enclosed; these spectra correspond to those known in the literature (B. Casu et al, Arzneim-Forsch. (Drug Research) 33, 135-142, 1983).
In figure 1, the peaks in the region 90-95 ppm (due to C-l anomeric carbon) and in the region 53-61 ppm (due to C-2 of amino sugar units) are particularly suitable in order to identify the different uronic units, to measure the amount of said units and to determine the sulfate group distribution on the uronic and hexosamine units.
In the present text the following abbreviations have been adopted:
L-iduronyl-2-sulfate = Ido A2S03 D-glucuronic acid = GlcA
Glucosamine N-sulfate = GlcNS03 25 N-acetyl glucosamine = GlcAc .:. .:, .
. . ~ ~ .. . :
.
Glucosamine with no substituted amine groups = GlcNH2 r = reducing terminal groups, mainly referred to hexosaminic units.
The following relative percentages were calculated by considering the areas under the characteristic peaks of different groups:
IdoA2S03 = 68.2%; GlcA = 31.8% referred to total uronic acids;
GlcNS03 = 37.8%; GlcNAc bound to IdoA2S03=37.8%: GlcNAc bound to GlcA = 11.0%; reducing GlcN = 13.4%, with respect to total hexosamines (C-1 peaks evaluated).
From the area under C-2 and CH3 (N-acetyl) peaks the GlcNS03 groups percentage amounts to 36.2%, and the percentage of total GlcNAc units amounts to 53%.
The product is analogous to Heparin (because of high IdoA2S03 unit content 71-91% of total uronic acid in Heparin) and to Heparansulfate (because of high N-acetyl group 58% content of total glucosamine Heparansulfate); but it differs in a considerable measure from abovementioned glycosaminoglicaes, because of predominant GlcNAc-IdoA2S~3 sequences which are in minor amount in both aforesaid GAG.
The example which follows, describes the original process Por the production of Heparin-like N-acetylated compound (f~nal product B) obtained from calcium Heparin. Based on laboratory models this compound shows fibrinolytic and antithrombotic .
, ~
.': ' activity, and lacks anticlotting activity. Therefore, the hemorraghic risk is low. The antithrombotic activity has been tested using a model on a rat's tail, according to Bekemeyer (Bekemeyer H. - Hirschelmann, "Agents and Actions". Vol.16 pag.
446 (1985)).
The fibrinolytic activity ex-vivo was tested on the plasma of rabbits $njected with the product through the evalutation of FDP (Fibrin Depolymerization Peptides), using the Bohringer Diagnostica Kit.
The method of production, as well as the complexes obtained and their use as fibrinolytic and protecting agents of thrombosis, are part of this invention.
The purification of the final product B and of the intermediate A are carried out following the general techniques, lS using ammonium quaternary salts and ethanol in saline solution, as described by Scott (Scott, J. Meth. Bioch. Analysis VIII 145-197 (1960)).
EXAMPLE
1) Preparation o~ the calcium Neparin:
100 g of Heparin sodium 150 IU/mg are dissolved in distilled water, a quantity sufficient for 1 liter of solution (10%). It is heated at 50 C and, in agitation, 120 g of cetiltrimethylammonium bromide (CTAB) dissolved in 1 liter of distilled water, are slowly added.
The precipitated is left still for 1 hour at said - ~ -: -. ,; ., :
J s~
temperature ad is separated by cetrifugation. It is washed twice with 100 ml each time, of 1% solution of CTAB in water, and finally the solid substance obtained is dissolved in 1 liter of 2M CaCl2 solution in water. Then, the polysaccharide is precipitated adding 1 volume of ethanol 96. It is settled during all night, the supernatant is put aside and the solid substance obtained is redissolved in 1 liter of 2 M CaC12 in acqueous solution.
The clear solution is precipitated again with a volume of ethanol 96. The solid substance is settled, redissolving for a second time in 1 liter 2 M CaC12. The rests of CTAB are eliminated by adding bentonite according to Scott ( Scott, J.
Meth. Bioch. Analysis VIII, 145-197 (1960)). The bentonite is eliminated by filtration and the clear liquid is precipitated for the last time with 1 volume of ethanol.
The solid substance is anhydrated with ethanol and dried in a vacuum drying chamber.
Then, 90 g of calcium Heparin are obtained with a degree of sodium inferior to 0.1%.
2) Preparation of the intermediate A:
The 90 g of calcium polysaccharide are dissolved by flowing back in HCl 0.25 M, a quantity sufficient to obtain a 10~
solution, heating at 80 C. After 2 hours, the N-desulfatation reaction is practically completed, which is evidenced by the absence of anticlotting activity of the liquid in reaction, and , :
the appearance of a strong calcium sulfate precipitate.
When the action desired is completed, the reaction is stopped adjusting the pH to 7 by adding a 10 M NaOH solution.
A sufficient quantity of 10% w/v C03Na2 solution is added to complete precipitation of CO~Ca, and the precipitate obtained is eliminated by filtration.
The polysaccharide N-desulfated is isolated from the liguid adding 1 vol. ethanol and it is settled during the whole night.
The heparaminic material is anhydrated and dried in vacuum drying 10 stoves.
Then, 60 g of material are obtained containing 50% of amino free groups (Intermediate A).
3) Preparation of the final product B:
g of intermediate A are dissolved in distilled H20, a sufficient quantity for 1 liter of solution (5% w/v) and the pH
is adjusted to 9,5 with 10 M NaOH solution. The temperature is raised to 25-28 C, and under agitation 5 ml of acetic anhydride are added drop by drop, maintaining the pH in 9,3 - 9,5 with a NaOH solution. The aggregate of acetic anhydride takes approximately 5 minutes and the reaction time under agitPtion is minutes, after which 10 g of NaCl are added. Then, all the liquid is precipitated in 1 vol. ethanol and settled for the whole night.
After it has been precipitated and settled, the paste is dissolved in 500 ml of sterile water, 5 g of NaCl are added, the .:
.
.,, ~ ~; , .
pH is adjusted to 6,0 with 6 M HCl and filtration is started using depyrogenic plates and sterilizing membranes of o,8 - 0,22 U. The liquid filtered is precipitated with 1 vol. ethanol filtered, it is anhydrated and dried in vacuum drying stoves at 60 C, during 12 hours.
g of N-acetylated product are obtained, without free amino groups, but with a chemical composition (see titration curve), analytical characteristics, and biological and pharmacological properties similar as a whole to the ones of the natural HS.
The analytical tipification of the original Heparin, the intermediate A complex and the final product B are shown here below.
.: , ,' ~ - ' ' ~ J~3~ , _ Ana]ytical Determ. Sodium Heparin Intermediate A Final Prod. B
APPT Activity150 IU/mg10 IU/mg 10 IU/mg Anti-X Activity150 lU/mg10 IU/mg 10 IU/mg N-acetyl 0,8% 0,9% 4.3%
Uronic acid 30,0% 35,0% 31,0X
Hexosamines 30.0% 35'0% 32,0%
Organic sulfate (as S) 11,0%8,2% 7,8%
Specific rotation + 36 ~ 40 1 40 Molar Relation uronic/
-hexosamine/S/acetyl 1:1:2,2:0,1 1:1:1,7:0,1 1:1:1,7:0,5 NH/N total 0,0 o,5 0,0 The figures 1 to 3 are the 13C-NMR spectra of the following compounds:
fig. 1: final product B; fig 2: Heparin; Fig. 3: Heparansulfate.
The figures 4 to 7 represent evalutations as per the following details:
fig. 4,6,7: B-A= carboxylic uronic groups A= sulfate groups fig. 5 : B-A= carboxylic uronic groups C-tB-A)= sulfate group~
C-B= free amino groups Therefore, being specially described and determined the nature of this patent application, and the corresponding way to .. ' put the same into effect, it is hereby claimed its exclusive right and property.
- ... ~........ .
: ,. ~, :: :: ; :: :
-: . : ~ \,~- ~ .
: : ~
ZO Therefore, said substances are specially relevant to cardiovascular medicine, mainly, in long-lasting therapies intended to prevent the formation of microthrombus, as well as to contribute to their dissolution. This can be achieved with little risk of hemorrhages and with reduced side ePfects.
Obviously, these natural mucopolysaccharides cannot be , ~
' ;
6~ ? r` ~
extracted in large scale, due to their low concentration in the tissular mass. This can limit significatively its extensive use in the therapeutical field.
Now, in accordance with the patent application, a process has been developed, which permits to obtain a pure N-acetilated compound with a Heparin-like structure with good yields, starting from Heparin as raw material.
The process of the invention is based upon a controlled hidrolysis of the Heparin with N-desulfatation without depolimerization, followed by the introduction of the acetyl group in the specific position of the aminic N, through a reaction using acetic anhydride.
The Heparin desulfatation is achieved specifically on the amino group, without hydrolizing the group O-sulfate and without producing hidrolysis of the glycosidic bond or other parasitic reactions. This has already been described by Inoue and Nagasawa (1975~ "Inoue, Y. - Nagasawa, K. Carbohyd, Res. 46, 87-95 (1976)". However, this method cannot be easily conducted at large scale, since it works on a heparin-piridynic complex dissolved in zO acqueous or methanolic dimetilsulfoxide with its associated problems, for example: the separation of the complex from the reacting solvent, the quantitative ellmination of the pyridine, the recovery o~ expensive solvents, etc.
On the contrary starting from calcium Heparin, due to the contra-ion size, a selective N-desulfatation in an acid acqueous .: ,: . :: . :
~ : : . : . ::.
medium can be achieved, without causing structural alterations and without affecting the medium MW.
Particularly, the browning of the product and the hydrolysis of the O-sulfate group are avoided.
Then, the partially N-desulfated Heparin (Intermediate A), is subjected to the acetylation reaction.
The Heparin acetylation has been described by Danishefsky (Danishefsky, N. Meth. Carb. Chem. ~, (85), 11) and Nagasawa as well (Inoue, Y. - Nagasawa, K. Carbohyd, Res. 46, 87-95 (1976)).
Both of them work with great quantities of acetic anhydride, pH-6,5-7,o and a wide range of temperatures.
In these conditions, and working at low temperatures lO-5 C), a parasitic O-acetylation is produced over the free -OH of the disaccharidic unit.
It has been discovered, and it is the object of the present invention, that when using a quantity practically stoichiometric of the acetic anhydride (1-1,1 moles (CH,CO) =O/Mol of the free-amino N, previously determined by the titration curve and at a pH
between to 9,3 and 9,5 (maximun limit compatible whit the acetic anhydride hydrolisis), the N-acetylation is exclusively produced, even working at 25-30C.
At this temperature, the reaction is fast and complete within 15 minutes. Even if the reaction is lasted for a longer time, it does not produce secondary reactions.
The obtained product (final product B) has an extremely .
constant composition and is represented by a molecule chemically well characterised, with a precise analitical description, as defined in the following table and figures.
To better identify the product object of the present invention the 3C-NMR characterisation of the product is hereby described.
The NMR spectrum of the final product 8 (figure 1), was determined in D20 solution, at 75 MHz, by means of a Brucker Mod.
CxP-300 spectrometer. For comparison purposes also the spectra of a standard Heparin (figure 2) ad of Heparansulfate tHS, figure 3) are enclosed; these spectra correspond to those known in the literature (B. Casu et al, Arzneim-Forsch. (Drug Research) 33, 135-142, 1983).
In figure 1, the peaks in the region 90-95 ppm (due to C-l anomeric carbon) and in the region 53-61 ppm (due to C-2 of amino sugar units) are particularly suitable in order to identify the different uronic units, to measure the amount of said units and to determine the sulfate group distribution on the uronic and hexosamine units.
In the present text the following abbreviations have been adopted:
L-iduronyl-2-sulfate = Ido A2S03 D-glucuronic acid = GlcA
Glucosamine N-sulfate = GlcNS03 25 N-acetyl glucosamine = GlcAc .:. .:, .
. . ~ ~ .. . :
.
Glucosamine with no substituted amine groups = GlcNH2 r = reducing terminal groups, mainly referred to hexosaminic units.
The following relative percentages were calculated by considering the areas under the characteristic peaks of different groups:
IdoA2S03 = 68.2%; GlcA = 31.8% referred to total uronic acids;
GlcNS03 = 37.8%; GlcNAc bound to IdoA2S03=37.8%: GlcNAc bound to GlcA = 11.0%; reducing GlcN = 13.4%, with respect to total hexosamines (C-1 peaks evaluated).
From the area under C-2 and CH3 (N-acetyl) peaks the GlcNS03 groups percentage amounts to 36.2%, and the percentage of total GlcNAc units amounts to 53%.
The product is analogous to Heparin (because of high IdoA2S03 unit content 71-91% of total uronic acid in Heparin) and to Heparansulfate (because of high N-acetyl group 58% content of total glucosamine Heparansulfate); but it differs in a considerable measure from abovementioned glycosaminoglicaes, because of predominant GlcNAc-IdoA2S~3 sequences which are in minor amount in both aforesaid GAG.
The example which follows, describes the original process Por the production of Heparin-like N-acetylated compound (f~nal product B) obtained from calcium Heparin. Based on laboratory models this compound shows fibrinolytic and antithrombotic .
, ~
.': ' activity, and lacks anticlotting activity. Therefore, the hemorraghic risk is low. The antithrombotic activity has been tested using a model on a rat's tail, according to Bekemeyer (Bekemeyer H. - Hirschelmann, "Agents and Actions". Vol.16 pag.
446 (1985)).
The fibrinolytic activity ex-vivo was tested on the plasma of rabbits $njected with the product through the evalutation of FDP (Fibrin Depolymerization Peptides), using the Bohringer Diagnostica Kit.
The method of production, as well as the complexes obtained and their use as fibrinolytic and protecting agents of thrombosis, are part of this invention.
The purification of the final product B and of the intermediate A are carried out following the general techniques, lS using ammonium quaternary salts and ethanol in saline solution, as described by Scott (Scott, J. Meth. Bioch. Analysis VIII 145-197 (1960)).
EXAMPLE
1) Preparation o~ the calcium Neparin:
100 g of Heparin sodium 150 IU/mg are dissolved in distilled water, a quantity sufficient for 1 liter of solution (10%). It is heated at 50 C and, in agitation, 120 g of cetiltrimethylammonium bromide (CTAB) dissolved in 1 liter of distilled water, are slowly added.
The precipitated is left still for 1 hour at said - ~ -: -. ,; ., :
J s~
temperature ad is separated by cetrifugation. It is washed twice with 100 ml each time, of 1% solution of CTAB in water, and finally the solid substance obtained is dissolved in 1 liter of 2M CaCl2 solution in water. Then, the polysaccharide is precipitated adding 1 volume of ethanol 96. It is settled during all night, the supernatant is put aside and the solid substance obtained is redissolved in 1 liter of 2 M CaC12 in acqueous solution.
The clear solution is precipitated again with a volume of ethanol 96. The solid substance is settled, redissolving for a second time in 1 liter 2 M CaC12. The rests of CTAB are eliminated by adding bentonite according to Scott ( Scott, J.
Meth. Bioch. Analysis VIII, 145-197 (1960)). The bentonite is eliminated by filtration and the clear liquid is precipitated for the last time with 1 volume of ethanol.
The solid substance is anhydrated with ethanol and dried in a vacuum drying chamber.
Then, 90 g of calcium Heparin are obtained with a degree of sodium inferior to 0.1%.
2) Preparation of the intermediate A:
The 90 g of calcium polysaccharide are dissolved by flowing back in HCl 0.25 M, a quantity sufficient to obtain a 10~
solution, heating at 80 C. After 2 hours, the N-desulfatation reaction is practically completed, which is evidenced by the absence of anticlotting activity of the liquid in reaction, and , :
the appearance of a strong calcium sulfate precipitate.
When the action desired is completed, the reaction is stopped adjusting the pH to 7 by adding a 10 M NaOH solution.
A sufficient quantity of 10% w/v C03Na2 solution is added to complete precipitation of CO~Ca, and the precipitate obtained is eliminated by filtration.
The polysaccharide N-desulfated is isolated from the liguid adding 1 vol. ethanol and it is settled during the whole night.
The heparaminic material is anhydrated and dried in vacuum drying 10 stoves.
Then, 60 g of material are obtained containing 50% of amino free groups (Intermediate A).
3) Preparation of the final product B:
g of intermediate A are dissolved in distilled H20, a sufficient quantity for 1 liter of solution (5% w/v) and the pH
is adjusted to 9,5 with 10 M NaOH solution. The temperature is raised to 25-28 C, and under agitation 5 ml of acetic anhydride are added drop by drop, maintaining the pH in 9,3 - 9,5 with a NaOH solution. The aggregate of acetic anhydride takes approximately 5 minutes and the reaction time under agitPtion is minutes, after which 10 g of NaCl are added. Then, all the liquid is precipitated in 1 vol. ethanol and settled for the whole night.
After it has been precipitated and settled, the paste is dissolved in 500 ml of sterile water, 5 g of NaCl are added, the .:
.
.,, ~ ~; , .
pH is adjusted to 6,0 with 6 M HCl and filtration is started using depyrogenic plates and sterilizing membranes of o,8 - 0,22 U. The liquid filtered is precipitated with 1 vol. ethanol filtered, it is anhydrated and dried in vacuum drying stoves at 60 C, during 12 hours.
g of N-acetylated product are obtained, without free amino groups, but with a chemical composition (see titration curve), analytical characteristics, and biological and pharmacological properties similar as a whole to the ones of the natural HS.
The analytical tipification of the original Heparin, the intermediate A complex and the final product B are shown here below.
.: , ,' ~ - ' ' ~ J~3~ , _ Ana]ytical Determ. Sodium Heparin Intermediate A Final Prod. B
APPT Activity150 IU/mg10 IU/mg 10 IU/mg Anti-X Activity150 lU/mg10 IU/mg 10 IU/mg N-acetyl 0,8% 0,9% 4.3%
Uronic acid 30,0% 35,0% 31,0X
Hexosamines 30.0% 35'0% 32,0%
Organic sulfate (as S) 11,0%8,2% 7,8%
Specific rotation + 36 ~ 40 1 40 Molar Relation uronic/
-hexosamine/S/acetyl 1:1:2,2:0,1 1:1:1,7:0,1 1:1:1,7:0,5 NH/N total 0,0 o,5 0,0 The figures 1 to 3 are the 13C-NMR spectra of the following compounds:
fig. 1: final product B; fig 2: Heparin; Fig. 3: Heparansulfate.
The figures 4 to 7 represent evalutations as per the following details:
fig. 4,6,7: B-A= carboxylic uronic groups A= sulfate groups fig. 5 : B-A= carboxylic uronic groups C-tB-A)= sulfate group~
C-B= free amino groups Therefore, being specially described and determined the nature of this patent application, and the corresponding way to .. ' put the same into effect, it is hereby claimed its exclusive right and property.
- ... ~........ .
: ,. ~, :: :: ; :: :
-: . : ~ \,~- ~ .
: : ~
Claims (3)
1. A process for the synthesis of a N-acetylated compound starting from Heparins, partially or completely N-desulfated, based on the titration of the free-amino groups in the N-desulfated Heparins, addition of the stoichiometric quantity of acetic anhydride in a ratio from 1 to 1,1 moles of acetic anhydride per mol of free-amino groups, at a pH comprised between 9.3 and 9.5. at a temperature between 25 and 30°C.
2. The product obtained from Heparin through the process described in claim 1, which presents the following analytical characteristics:
- Anticlottig activity (APTT-Anti-X): less than 10 IU/mg.
- N-acetyl content (expressed as CH3CO-) : 3 - 7% w/w corresponding to a degree of N-acetylation from 40 to 90%
- Uronic acids (post hydrolysis) : 31 ? 1%
- Hexosamines (post hydrolysis) : 32 ? 1%
- Organic sulfate (as S) : 8 ? 1%
- Molar ratio uronic/hexosamine/S/acetyl : 1:1:1.5-1.7:0.4-0.9 - Specific optical rotation : > + 35°.
- Anticlottig activity (APTT-Anti-X): less than 10 IU/mg.
- N-acetyl content (expressed as CH3CO-) : 3 - 7% w/w corresponding to a degree of N-acetylation from 40 to 90%
- Uronic acids (post hydrolysis) : 31 ? 1%
- Hexosamines (post hydrolysis) : 32 ? 1%
- Organic sulfate (as S) : 8 ? 1%
- Molar ratio uronic/hexosamine/S/acetyl : 1:1:1.5-1.7:0.4-0.9 - Specific optical rotation : > + 35°.
3. Pharmaceutical compositions containing the product as defined in claim 2, as a unique active ingredient with antithrombotic and fibrinolitic properties, with low anticlotting activity, apt to oral and injectable use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2023367 CA2023367A1 (en) | 1989-08-18 | 1990-08-15 | Substances with heparin-like structure and their method of production |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AR314703 | 1989-08-18 | ||
| CA 2023367 CA2023367A1 (en) | 1989-08-18 | 1990-08-15 | Substances with heparin-like structure and their method of production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2023367A1 true CA2023367A1 (en) | 1991-02-19 |
Family
ID=4145744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2023367 Abandoned CA2023367A1 (en) | 1989-08-18 | 1990-08-15 | Substances with heparin-like structure and their method of production |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2023367A1 (en) |
-
1990
- 1990-08-15 CA CA 2023367 patent/CA2023367A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pouyani et al. | Functionalized derivatives of hyaluronic acid oligosaccharides: drug carriers and novel biomaterials | |
| EP0340628B1 (en) | Sulfoamino derivatives of chondroitin sulfates, of dermaten sulfate and of hyaluronic acid and their pharmacological properties | |
| EP0557887B1 (en) | Polysaccharide derivatives of heparin, heparan sulphate, fraction and fragments thereof, process for their preparation and pharmaceutical compositions containing them | |
| HU214986B (en) | Process for producing preparation containing n,o-sulfated heparosanes | |
| DE68916878T2 (en) | Selectively O-acylated glycosaminoglycans. | |
| US4948881A (en) | Process for the depolymerization and sulfation of polysaccharides | |
| US8492352B2 (en) | Polysaccharides with antithrombotic activity, including a covalent bond and an amino chain | |
| Tamura et al. | Synthesis of chondroitin sulfate E octasaccharide in a repeating region involving an acetamide auxiliary | |
| CA2285383C (en) | Glycosaminoglycans having high antithrombotic activity | |
| Zhang et al. | Expedient Synthesis of a Library of Heparan Sulfate‐Like “Head‐to‐Tail” Linked Multimers for Structure and Activity Relationship Studies | |
| US5340932A (en) | Substances with heparin-like structure and their method of production | |
| JP4695756B2 (en) | Novel pentasaccharide, process for producing the same and pharmaceutical composition containing the same | |
| RU2283319C2 (en) | Glycosaminoglycans, derivatives of k5 polysaccharide, possessing high anti-coagulant and anti-thrombosis activity and method for their preparing | |
| Linhardt et al. | New methodologies in heparin structure analysis and the generation of LMW heparins | |
| EP0413248B1 (en) | Substances with heparin-like structure and their method of production | |
| JP5053512B2 (en) | Epimerized derivatives of K5 polysaccharide with very high degree of sulfation | |
| US20060223781A1 (en) | Process for induction of intramolecular migration of sulfates, phosphates, and other oxyanions | |
| US7005508B2 (en) | Nitroderivatives of polysaccharides | |
| EP1694714B1 (en) | Low molecular weight polysaccharides having antithrombotic activity | |
| Zhang et al. | An efficient anticoagulant candidate: Characterization, synthesis and in vivo study of a fondaparinux analogue Rrt1. 17 | |
| CA2023367A1 (en) | Substances with heparin-like structure and their method of production | |
| CN113666980A (en) | High-selectivity factor Xa inhibitor heparin heptasaccharide and preparation method and application thereof | |
| WO1994029352A1 (en) | Polysaccharides having high antithrombotic and anticoagulant activity | |
| CN110698522B (en) | Odd-numbered chondroitin oligosaccharide monomer and preparation method and application thereof | |
| RU2333222C2 (en) | Epimerised k5 polysaccharide derivatives with high sulfation degree |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |